StockData

CRISPR Therapeutics vs X4 Pharmaceuticals

CRSP and XFOR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRSP and XFOR compare

CRISPR Therapeutics is the larger company, worth 13 times as much as X4 Pharmaceuticals ($3.9B against $306M).

X4 Pharmaceuticals grew revenue faster over the last twelve months (73.7% versus −64.8% for CRISPR Therapeutics).

X4 Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −813% compared with −3369% at CRISPR Therapeutics.

CRISPR Therapeutics scores higher on the StockData Score (8 against 3 for X4 Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRSPXFOR
Size and price
Market cap$3.9B$306M
Share price$40.15$3.09
Change, 1 year−23.6%−15.6%
Change, 5 years−49.0%−97.7%
Beta (5Y)1.591.45
Employees39345
StockData Score
Total score8 (better)3
Valuation score00
Growth score12 (better)
Performance score2 (better)0
Health score5 (better)1
Dividend score00
Valuation
P/S290×30.9× (better)
P/B2.2×2.2× (better)
FCF yield−9.6%–
Growth
Revenue growth (TTM)−64.8%73.7% (better)
Revenue growth, 5Y average37.3% (better)16.7%
Profitability
Gross margin–68.8%
Operating margin−3990%−812% (better)
Net margin−3369%−813% (better)
FCF margin−2773%–
Return on equity−26.1% (better)−80.3%
Financial health
Debt / equity0.00–
Interest coverage–−9.3×
Current ratio17.85 (better)13.22
Altman Z-score1.79 (better)−2.11
Piotroski F-score24 (better)
Dividends and buybacks
Buyback yield−10.0%–
Shareholder yield−10.0%0.00% (better)
Ownership
Held by institutions78.9%103%
Held by insiders2.7%12.2%
Insider net buying, 12 months−$17.9M−$451K (better)
Short interest, % of float18.3%9.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.